Collegium Pharmaceutical Inc Dossier
Qualitative Analysis
Business overview
Collegium Pharmaceutical, Inc. is a diversified specialty biopharmaceutical company dedicated to improving the lives of people living with serious medical conditions. The company has built a robust commercial portfolio focused on two primary therapeutic pillars: pain management and attention deficit hyperactivity disorder (ADHD). Its leading pain products include Belbuca, Xtampza ER, and the Nucynta franchise (Nucynta ER and Nucynta IR). In ADHD and neuropsychiatry, Collegium has rapidly expanded its footprint, anchored by Jornay PM (acquired in late 2024) and the newly completed acquisition of AZSTARYS in May 2026.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding and commercializing the ADHD franchise by leveraging the newly acquired AZSTARYS alongside JORNAY PM, utilizing existing commercial infrastructure and sales forces.
Expected impact: Extends the longevity of Collegium's revenue base into the late 2030s (with patent protection through December 2037) and diversifies the business beyond pain management.
Maximizing the durability and profitability of the core pain management portfolio (including BELBUCA, Xtampza ER, and the NUCYNTA franchise) through strong commercial execution and brand fundamentals.
Expected impact: Maintains steady cash flow generation to fund debt paydown, share repurchases, and business development.
Executing a disciplined capital deployment strategy that balances paying down debt, opportunistically repurchasing shares, and evaluating portfolio expansion opportunities.
Expected impact: Aims to rapidly pay down debt incurred from the AZSTARYS transaction (targeting a return to low leverage levels) and enhance long-term shareholder value.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire the global rights and intellectual property of AZSTARYS, a complementary and differentiated ADHD stimulant, to strengthen Collegium's position in the ADHD market and extend revenue durability.
Financial impact: Expected to generate $60 million to $70 million in net revenue for the remainder of 2026, deliver over $50 million in annual run-rate synergies within 12 months, and be immediately accretive to adjusted EBITDA.
Strategic Partnerships
Grants Hikma the exclusive right to sell Collegium-supplied authorized generic versions of Nucynta and Nucynta ER in the United States.
Terms: Collegium will receive a significant share of net profits from the sales of the AG products.